Valproate use in men: as a precaution, men and their partners should use effective contraception (5 September 2024)

Summary

A retrospective observational study has indicated a possible association between valproate use by men around the time of conception and an increased risk of neurodevelopmental disorders in their children. This Drug Safety Update advises to inform male patients who may father children of this possible increased risk and the recommendation to use effective contraception during valproate treatment and for at least 3 months after stopping valproate.

Follow the link below to read the full Drug Safety Update issued on 5 September 2024 by the Medicines and Healthcare products Regulatory Agency.